Ependymoma

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This study tests a combination of a vaccine targeting the CMV virus (PEP-CMV) and an immunotherapy drug (nivolumab) in children and young adults with certain aggressive brain tumors, including diffuse midline glioma and medulloblastoma. The goal is to see if this approach is safe…

This Phase I trial tests whether infusing specially trained immune cells, called TAA-T, can safely target and attack high-risk brain tumors in children and adults. The cells are made from the patient's own blood and are designed to recognize multiple tumor-related proteins, poten…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This Phase 2 trial tests a new approach for children whose medulloblastoma or ependymoma has come back. It combines a radioactive antibody (omburtamab) delivered directly into the brain's fluid spaces with standard chemotherapy drugs. The goal is to see if this combination can he…

This early-stage trial is testing the safety and potential benefit of pembrolizumab, an immunotherapy drug, in 71 children whose brain tumors (like DIPG, high-grade gliomas, or medulloblastoma) have come back or not responded to standard treatments. The drug works by helping the …

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery …

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This early-stage trial tests a new treatment for children and young adults up to age 21 with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a pro…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This early-stage trial tests a new treatment for children whose ependymoma brain tumor has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells that carry a protein called HER2. Th…

This early-phase study tests a vaccine called SurVaxM in 35 children with certain brain tumors that have come back or are hard to treat. The vaccine is designed to teach the immune system to find and destroy tumor cells that have a protein called survivin. The goal is to see if i…

This study tests the Optune device, a wearable cap that creates low-intensity electric fields to disrupt cancer cell growth, in children with aggressive brain tumors. One group of children with recurrent high-grade glioma or ependymoma will use the device alone to see if it's fea…

This clinical trial tests a risk-adapted approach for young children with newly diagnosed brain tumors. The treatment starts with chemotherapy to delay radiation, giving the brain more time to develop. Then, radiation is carefully targeted to the tumor area to reduce side effects…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…

This early-phase trial tests a new treatment for adults with aggressive brain cancers (glioblastoma, ependymoma, or medulloblastoma) that have spread to the lining of the brain and spinal cord. The treatment uses the patient's own immune cells, modified in a lab to recognize and …

This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…

This study tests whether surgery followed by a second course of radiation can help children and young adults (ages 1-21) whose ependymoma has returned after initial treatment. The combined radiation dose is higher than standard. Researchers will track how long the tumor stays und…

This study aimed to test a new way to treat brain tumors that came back after standard therapy. The plan was to deliver immunotherapy (nivolumab) plus chemotherapy directly into the fluid spaces of the brain in children and adults. However, the study was withdrawn before any part…

This study tests whether adding an experimental drug called indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers. The drug aims to boost the body's immune system to fight tumors more effectively. The trial includes children wi…

This early-stage trial tests a new approach for children whose high-grade glioma has come back after standard treatments. It combines specially grown stem cells with an immunotherapy drug called nivolumab. The main goals are to see if the treatment is safe and possible to deliver…

This early-phase study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The therapy a…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This was a very early phase 1 trial that planned to test a personalized immune cell therapy for people with recurrent glioblastoma, an aggressive brain cancer. The treatment involved taking a patient's own T cells, activating them in a lab to target cancer stem cells, and giving …

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This study tests a special proton radiation method for children with brain tumors that need radiation to the brain and spine. The new approach spares parts of the backbone to reduce side effects like low blood counts and slowed bone growth. About 20 children aged 3 to 18 will rec…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…